gabapentin 600 mg recall 2025 does gabapentin affect breast milk

Gabapentin is being recalled due to a potential issue with empty capsules within certain batches. This isn’t a widespread recall of all gabapentin products, but rather a specific batch of 300 mg capsules manufactured by Aurobindo Pharma USA. Drug Recall Enforcement Report Class III voluntary initiated by The Harvard Drug Group, originally initiated on 04-24-2023 for the product Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 The starting dose is 300 mg three times a day. The recommended maintenance dose of gabapentin is 300 mg to 600 mg three times a day. Dosages up to 2,400 mg/day have been well tolerated in long-term clinical studies. The last Recall Enforcement Report for Gabapentin with NDC 50228-178 was initiated on 02-17-2023 as a Class III recall due to presence of foreign tablets/capsules: pharmacist reported presence of some gabapentin tablets 800 mg comingled in gabapentin 600 mg 500 count bottles. Nerve Pain, Seizure Drug Recalled. The Harvard Drug Group is pulling 3984 cartons of gabapentin tablets after a foreign tablet was found in a carton, according to the May 17, 2023, US Food and Drug Administration (FDA) Enforcement Report. The list below provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on The last Recall Enforcement Report for Gabapentin with NDC 0904-6823 was initiated on 04-24-2023 as a Class III recall due to product mixup: one foreign tablet found in product. The latest recall number for this product is D-0570-2023 and the recall is currently terminated as of 04-30-2024 . encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required. GRANULES PHARMACEUTICALS INC. is recalling Gabapentin Tablets USP, 600mg. This recall is due to a potential mix-up of Metformin ER Tablets in a bottle of Gabapentin Tablets, USP 600mg. Drug Recalls Lookup; Pill ID Lookup; 310433 - gabapentin 600 MG Oral Tablet; 2025 if the product is not updated or renewed by the manufacturer. Aurobindo Pharma USA, Inc, of Dayton, NJ, has issued a voluntary recall of one lot (Lot Number GESB14011-A) of gabapentin capsules, USP 300 mg, 100-count bottles to the consumer level after finding that some capsules were empty. The last Recall Enforcement Report for Gabapentin with NDC 70010-228 was initiated on 07-31-2024 as a Class II recall due to presence of foreign tablets; 3 fused tablets of metformin er 500 mg were found in bottle of gabapentin tablets The latest recall number for this product is D-0634-2024 and the recall is currently ongoing . Most recalls are limited to a single manufacturer and may not be related to the version of a particular drug you are taking. gabapentin tablets, 600 mg, 500-count On August 7, 2024, the U.S. Food and Drug Administration (FDA) approved Purdue Pharma's Zurnai® (nalmefene) autoinjector for emergency treatment of opioid overdose in individuals aged 12 years and older. Drug Recall Enforcement Report Class II voluntary initiated by Granules Pharmaceuticals Inc., originally initiated on 07-31-2024 for the product Gabapentin Tablets, USP, 600 mg, 500-count bottles, Rx only, Manufactured by: Granules India Limited Hyderabad-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA NDC 70010-227-05 The product was recalled due to presence of FDA Announces Voluntarily Recall for Batch of Gabapentin 300 MG Capsules Epilepsy News From: Tuesday, November 25, 2014 The U.S. Food and Drug Administration (FDA) has reported that Aurobindo Pharma USA is voluntarily recalling Gabapentin 300 mg capsules from lot GESB14011-A in 100-count bottles. The last Recall Enforcement Report for Gabapentin with NDC 70010-227 was initiated on 07-31-2024 as a Class II recall and it is currently ongoing. Drug Recall Enforcement Report Class III voluntary initiated by Sciegen Pharmaceuticals Inc, originally initiated on 02-17-2023 for the product Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05. Visit Recalls, Market Withdrawals, & Safety Alerts for all FDA-regulated products. Follow FDA Recall Information on X (formerly Twitter). FDA provides a searchable list of recalled products. Mandated? Product mixup: one foreign tablet found in product. On 03/12/2025, Safecor Health, LLC recalled LORAZEPAM 2 MG/ML due to Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes. The U.S. Food and Drug Administration (FDA) has issued a Class II Recall of the affected medications.

gabapentin 600 mg recall 2025 does gabapentin affect breast milk
Rating 5 stars - 727 reviews




Blog

Articles and news, personal stories, interviews with experts.

Video